Rinkel G J, Wijdicks E F, Vermeulen M, Hasan D, Brouwers P J, van Gijn J
Department of Neurology, University Hospitals, Utrecht, The Netherlands.
Ann Neurol. 1991 May;29(5):463-8. doi: 10.1002/ana.410290503.
We studied the early clinical course of 65 patients with perimesencephalic (nonaneurysmal) subarachnoid hemorrhage. None of the patients rebled; none had delayed cerebral ischemia; and only 3 patients (5%) developed clinical signs of acute hydrocephalus, 2 requiring ventricular shunting. Hyponatremia and electrocardiographic changes were found in the same proportions as in patients with aneurysmal rupture. All patients had a good outcome after 3 months. To control for the influence of the relatively small amount of cisternal blood in perimesencephalic hemorrhage on the absence of delayed cerebral ischemia, we compared these 65 patients with 49 patients who had aneurysmal subarachnoid hemorrhage. This control group with aneurysms was selected according to a similar amount of cisternal blood, a comparable level of consciousness on admission, and absence of other factors known to increase the risk for delayed cerebral ischemia. We found that 4 of the 49 patients with aneurysmal hemorrhage developed delayed cerebral ischemia (Fisher's exact test, p = 0.03); therefore the relatively small amount of blood does not account for the absence of delayed cerebral ischemia in perimesencephalic hemorrhage. Patients with a perimesencephalic pattern of hemorrhage and a normal angiogram should be considered to have a distinct subset of subarachnoid hemorrhage and should be excluded from future treatment trials of patients with subarachnoid hemorrhage.
我们研究了65例中脑周围(非动脉瘤性)蛛网膜下腔出血患者的早期临床病程。所有患者均未再出血;均未发生迟发性脑缺血;仅有3例患者(5%)出现急性脑积水的临床症状,其中2例需要进行脑室分流术。低钠血症和心电图改变的发生率与动脉瘤破裂患者相同。所有患者在3个月后预后良好。为了控制中脑周围出血时脑池内相对少量的血液对未发生迟发性脑缺血的影响,我们将这65例患者与49例动脉瘤性蛛网膜下腔出血患者进行了比较。该动脉瘤对照组是根据相似的脑池内血量、入院时相当的意识水平以及不存在其他已知会增加迟发性脑缺血风险的因素来选择的。我们发现,49例动脉瘤性出血患者中有4例发生了迟发性脑缺血(Fisher精确检验,p = 0.03);因此,相对少量的血液并不能解释中脑周围出血时未发生迟发性脑缺血的原因。具有中脑周围出血模式且血管造影正常的患者应被视为蛛网膜下腔出血的一个独特亚组,并且应被排除在未来蛛网膜下腔出血患者的治疗试验之外。